3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
UNKNOWN
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
4
Breast Neoplasms
3
Multiple Myeloma
2
Fallopian Tube Neoplasms
2
Stomach Neoplasms
1
Sarcoma
1
Platinum-resistant Recurrent Ovarian Cancer
1
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
1
Ovarian Cancer Recurrent
1
Lymphoma, Follicular
1
Lymphoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Ovarian Cancer
1
Interventions
Bevacizumab
2
tremelimumab
1
durvalumab
1
Paclitaxel
1
Injections
1
Docetaxel
1
1-dodecylpyridoxal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Platinum-resistant Recurrent Ovarian Cancer
×
1-dodecylpyridoxal
×
Clear all
NCT04348032
2022-03-31
APPROVE
ChineseAMS
Phase 2
Unknown
152 enrolled